The company’s latest 3D ultrasound offering includes advanced AI and other innovative features. It aims to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts.

GE HealthCare announced the new offering at the same time that it is expanding its AI partnership with Nvidia to include autonomous X-ray and ultrasound applications.  (We have a full roundup of medtech AI news out of Nvidia’s GTC 2025 event this week.)

The Chicago-based medtech giant says approximately 71% of cancers occur in dense breasts. Studies across the U.S. and Europe show 40% of women (plus 70% of Asian women) have dense breast tissue, the company says. It notes growing evidence supporting ABUS as a tool for detecting cancer in these dense breasts with clearer, more detailed images. ABUS also can improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography.